Magenta Therapeutics Inc (NASDAQ:MGTA) insider Michael P. Cooke sold 7,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $13.00, for a total value of $97,500.00. Following the sale, the insider now owns 244,396 shares of the company’s stock, valued at $3,177,148. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of MGTA stock traded down $0.80 during trading hours on Monday, reaching $12.44. The company had a trading volume of 169,861 shares, compared to its average volume of 126,255. Magenta Therapeutics Inc has a twelve month low of $5.31 and a twelve month high of $21.00. The company has a market capitalization of $516.22 million, a P/E ratio of -3.97 and a beta of 3.24. The stock’s fifty day simple moving average is $10.87 and its 200 day simple moving average is $12.29.
Magenta Therapeutics (NASDAQ:MGTA) last posted its earnings results on Wednesday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.54). Research analysts forecast that Magenta Therapeutics Inc will post -2.01 earnings per share for the current year.
Several equities research analysts have commented on the company. ValuEngine lowered Magenta Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Cowen restated a “buy” rating on shares of Magenta Therapeutics in a research note on Wednesday, November 13th. Finally, Zacks Investment Research lowered Magenta Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $16.33.
About Magenta Therapeutics
Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases.
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.